We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01825096
Recruitment Status : Completed
First Posted : April 5, 2013
Last Update Posted : January 5, 2017
Sponsor:
Information provided by (Responsible Party):
Lisa Nickerson, PhD, Mclean Hospital

Brief Summary:

The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availability, relatively high spatiotemporal resolution, and the ability to map function over the entire brain. Thus, BOLD fMRI is the most widely applied technology to study healthy brain function and pathophysiology associated with disease. In studies of drug abuse and psychiatric illness though, normal assumptions mapping BOLD signals to neurometabolism may be violated. Generally, these effects are ignored, resulting in large study-to-study variability.

Quantitative fMRI (qfMRI) measures metabolism directly and is more suitable for studies of drug abuse and psychiatric illness. However, qfMRI is too complex for routine use. Cerebral metabolism during brain activation during visual stimulation measured with a new fMRI approach that is simple enough for clinical applications will be compared to CMRO2 activation measured using standard qfMRI.


Condition or disease
Healthy

Detailed Description:
Healthy subjects will undergo a single imaging session. During the imaging session, fMRI and simultaneous near-infrared spectroscopy measurements will be made during visual stimulation (e.g., viewing a flashing checkerboard). This is a methods development study focused on comparing a new method for estimating CMRO2 associated with brain activation with the standard fMRI approach for estimating CMRO2.

Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Case-Only
Official Title: Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems
Study Start Date : March 2012
Primary Completion Date : December 2015
Study Completion Date : December 2015

Group/Cohort
baseline
No intervention. Participants are scanned at baseline.



Primary Outcome Measures :
  1. Changes in brain activity associated with visual stimulation [ Time Frame: cross-sectional, start and up to 6 minutes ]
    CMRO2 brain activation in visual cortex associated with visual stimulation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
1 healthy subject will be recruited for the study from the general population to undergo 12 separate study visits.
Criteria

Inclusion Criteria:

  • Male
  • 18 to 40 years old
  • Physically healthy by self-report

Exclusion Criteria:

Diagnosis of current drug abuse/dependence, including nicotine, as assessed by DSM-IV criteria

  • Current diagnosis of Axis I disorder using DSM-IV criteria, or any Axis I disorder within past 5 years
  • Current daily use of antipsychotic, antidepressant, or other psychoactive prescription drug, as well as daily use of non-prescription drugs
  • Life threatening or unstable medical illness, or one that can create marked change in mental state
  • Heavy caffeine use (greater than 300 mg on a regular, daily basis)
  • History of seizure disorder
  • Subjects that report any history or current major medical illness (cardiovascular, pulmonary, psychiatric, or neurological disorders)
  • Subjects who have metal in their body or suffer from claustrophobia cannot participate in this research study.
  • Additional MR exclusion criteria may include people with:
  • Cardiac pacemakers
  • Metal clips on blood vessels (also called stents)
  • Artificial heart valves
  • Artificial arms, hands, legs, etc.
  • Brain stimulator devices
  • Implanted drug pumps
  • Ear implants
  • Eye implants or known metal fragments in eyes
  • Exposure to shrapnel or metal filings (wounded in military combat, sheet metal workers, welders, and others)
  • Other metallic surgical hardware in vital areas
  • Certain tattoos with metallic ink (subjects are asked to inform research staff if they have a tattoo)
  • Metal Containing Intrauterine Devices (IUDs).
  • Certain transdermal (skin) patches such as Transderm Scop (scopolamine for motion sickness).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01825096


Locations
United States, Massachusetts
McLean Imaging Center
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
Investigators
Principal Investigator: Lisa D Nickerson, PhD Mclean Hospital

Responsible Party: Lisa Nickerson, PhD, Assistant Physicist, Mclean Hospital
ClinicalTrials.gov Identifier: NCT01825096     History of Changes
Other Study ID Numbers: 2012p00622
First Posted: April 5, 2013    Key Record Dates
Last Update Posted: January 5, 2017
Last Verified: January 2017

Keywords provided by Lisa Nickerson, PhD, Mclean Hospital:
cerebral metabolism
functional magnetic resonance imaging
near infrared spectroscopy